Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China

OBJECTIVE: The ASTRUM-005 trial demonstrated that adding serplulimab to chemotherapy significantly prolonged the survival of patients with extensive-stage small cell lung cancer (SCLC), but also increased the risk of adverse events. Given the high cost of serplulimab compared to chemotherapy, this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Guiyuan, Jiang, Tingting, Gan, Lanlan, Wu, Yuanlin, Zhang, Ni, Xing, Haiyan, Su, Hui, Li, Yanping, Peng, Dan, Ni, Rui, Liu, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501445/
https://www.ncbi.nlm.nih.gov/pubmed/37720211
http://dx.doi.org/10.3389/fimmu.2023.1223020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501445/
https://www.ncbi.nlm.nih.gov/pubmed/37720211
http://dx.doi.org/10.3389/fimmu.2023.1223020

Ejemplares similares